Erratum: Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analogue, liraglutide (International Journal of Obesity (2011) 36 (890) DOI: 10.1038/ijo.2011.158);Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide

International Journal of Obesity

Volumn 36, Issue 6, 2012, Pages 843-854

  Astrup, A ^a   Carraro, R ^b   Finer, N ^c   Harper, A ^d   Kunesova, M ^e   Lean, M E J ^f   Niskanen, L ^g   Rasmussen, M F ^h   Rissanen, A ⁱ   Rossner S ^j   Savolainen, M J ^k   Van Gaal, L ^l  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d NOVO NORDISK A S   (Denmark)

^e INSTITUTE OF ENDOCRINOLOGY   (Czech Republic)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h NOVO NORDISK INC   (United States)

ⁱ HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^j KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^k UNIVERSITY OF OULU   (Finland)

^l ANTWERP UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

GLP 1 analog; liraglutide; weight loss

Indexed keywords

LIRAGLUTIDE; PLACEBO; TETRAHYDROLIPSTATIN;

ABDOMINAL PAIN; ACUTE STRESS DISORDER; ADULT; AGED; ALCOHOL ABUSE; ANXIETY; ARTICLE; BODY FAT; BURNOUT; CARDIOVASCULAR RISK; CONSTIPATION; CONTROLLED STUDY; DEPRESSION; DIARRHEA; DIET; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EATING DISORDER; EUROPE; EVENING DOSAGE; EXERCISE; FEMALE; FLATULENCE; FOOD AVERSION; GASTROINTESTINAL DISEASE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL INSTABILITY; METABOLIC SYNDROME X; MOOD CHANGE; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; OBESITY; PATIENT COUNSELING; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; SIDE EFFECT; STEATORRHEA; STRESS; TREATMENT DURATION; UPPER ABDOMINAL PAIN; VOMITING; WEIGHT REDUCTION;

EID: 84862207266     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/ijo.2011.203     Document Type: Erratum

References (30)

1. Willett WC, Dietz WH, Colditz GA. Guidelines for healthy weight. N Engl J Med 1999; 341: 427-434. (Pubitemid 29362517)
2. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006; 444: 875-880. (Pubitemid 46028447)
3. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. (Pubitemid 34437694)
4. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in AdultsFThe Evidence Report. Obes Res 1998; 6(Suppl 2): 51S-209S.
5. Mertens IL, Van Gaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res 2000; 8: 270-278.
6. Avenell A, Broom J, Brown TJ, Poobalan A, Aucott L, Stearns SC et al. Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health Technol Assess 2004; 8: iii-iv, 1.
7. Food and Drug Administration. FDA Guidance for Industry: developing products for weight management, 2007.
8. NHS, National Institute for Health and Clinical Excellence. Obesity-guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children. NICE clinical guideline 43, 2006.
9. EMEA, Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical evaluation of medicinal products used in weight control, 15 November 2007.
10. Garber A, Henry R, Ratner R, Garcia-Hernandez PA, Rodriguez-Pattzi H, Olvera-Alvarez I et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
11. Vilsboll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O, Courrèges JP et al. Liraglutide, a long-acting human glucagonlike peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30: 1608-1610. (Pubitemid 46871185)
12. Astrup A, Rossner S, Van Gaal L, Rissanen A, Niskanen L, Al Hakim M et al. Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study. Lancet 2009; 374: 1606-1616.
13. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. JAMA 2000; 284: 3043-3045.
14. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-3167. (Pubitemid 37339514)
15. National Cholesterol Education Program. Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002; 106: 3143-3421.
16. Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: report of the national heart, lung, and blood institute/American heart association conference on scientific issues related to definition. Circulation 2004; 109: 433-438. (Pubitemid 38133916)
17. Kolotkin RL, Crosby RD, Kosloski KD,Williams GR. Development of a brief measure to assess quality of life in obesity. Obes Res 2001; 9: 102-111. (Pubitemid 33603836)
18. Knudsen LB, Madsen LW, Andersen S, Almholt K, de Boer AS, Drucker DJ et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and Ccell proliferation. Endocrinology 2010; 151: 1473-1486.
19. Li Z, Maglione M, Tu W, Mojica W, Arterburn D, Shugarman LR et al. Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 2005; 142: 532-546.
20. Dunnett CW. A multiple comparisons procedure for comparing several treatments with a control. J Am Stat Assoc 1955; 50: 1096-1121.
21. Padwal R, Li SK, Lau DC. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 2004; 3: CD004094.
22. Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G et al. X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet. Early response to treatment predicts weight maintenance. Diabetes Obes Metab 2005; 7: 699-708. (Pubitemid 41601074)
23. McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension-a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 2000; 160: 2185-2191. (Pubitemid 30482726)
24. Nguyen XM, Lane J, Smith BR, Nguyen NT. Changes in inflammatory biomarkers across weight classes in a representative US population: a link between obesity and inflammation. J Gastrointest Surg 2009; 13: 1205-1212.
25. Pi-Sunyer FX. The relation of adipose tissue to cardiometabolic risk. Clin Cornerstone 2006; 8(Suppl 4): S14-S23.
26. Belza A, Toubro S, Stender S, Astrup A. Effect of diet-induced energy deficit and body fat reduction on high-sensitive CRP and other inflammatory markers in obese subjects. Int J Obes 2009; 33: 456-464.
27. Courreges JP, Vilsbøll T, Zdravkovic M, Le-Thi T, Krarup T, Schmitz O et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008; 25: 1125-1131.
28. Astrup A. Is cardiometabolic risk improved by weight-loss drugs? Lancet 2010; 376: 595-605.
29. James WPT, Caterson ID, Coutinho W, Finer N, Van Gaal LF, Maggioni AP et al. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med 2010; 363: 905-917.
30. Muls E, Kolanowski J, Scheen A, Van GL. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001; 25: 1713-1721. (Pubitemid 33052084)